Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond

Fineline Cube Mar 30, 2026
Company Deals

Sinovac Biotech and Indonesia’s Bio Farma Forge Strategic Alliance to Expand Vaccine Access Across Developing Markets

Fineline Cube Mar 30, 2026
Company Deals

BrainAurora Medical Partners with Tokyo Lifestyle to Launch AI-Powered Digital Health Platform for Elderly Cognitive Care Across Asia

Fineline Cube Mar 30, 2026
Company Deals

C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market

Fineline Cube Mar 27, 2026
Company Deals

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

Fineline Cube Mar 26, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

J&J’s Icotyde Sustains and Improves Complete Skin Clearance in Psoriasis Through 52 Weeks, Outperforming Deucravacitinib on Safety

Fineline Cube Mar 30, 2026
Company Drug

Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Apremilast and Placebo in Phase III Psoriasis Trials with Unprecedented TYK2 Selectivity

Fineline Cube Mar 30, 2026
Company Drug

Neurophth Biotechnology Completes Enrollment and Dosing in US Clinical Study for ND4-LHON Gene Therapy

Fineline Cube Feb 20, 2024

Neurophth Biotechnology Ltd, a leading gene therapy specialist based in China, has announced the completion...

Company Deals

Biocytogen Pharmaceuticals Inks Antibody Evaluation Deal with Gilead Sciences

Fineline Cube Feb 20, 2024

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced an antibody...

Company Deals

Evopoint Biosciences Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization

Fineline Cube Feb 20, 2024

Evopoint Biosciences Co., Ltd., a Suzhou-based biopharmaceutical company, has announced the successful completion of a...

Company Drug

Phanes Therapeutics’ PT886 Receives CDE Approval for Clinical Trials in Advanced Solid Tumors

Fineline Cube Feb 20, 2024

Sino-US biotechnology company Phanes Therapeutics Inc. has announced that it has received clinical trial approval...

Company Drug

ImmunoTech Biopharm Gets NMPA Green Light for Clinical Study of aT19 Injection for B-ALL

Fineline Cube Feb 20, 2024

ImmunoTech Biopharm Ltd (HKG: 6978), a specialist in chimeric antigen receptor T-cell (CAR-T) therapies based...

Policy / Regulatory

Beijing, Tianjin, and Hebei Release Draft Proposal for Updated Drug Clinical Trial Inspection Standards

Fineline Cube Feb 20, 2024

The medical products administration bureaus of Beijing, Tianjin, and Hebei province have released a draft...

Company Drug

AstraZeneca’s Tagrisso Wins Expanded FDA Approval for EGFR-mutated NSCLC

Fineline Cube Feb 20, 2024

UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has received a new indication approval from the...

Company Drug

Innovent Biologics’ IBI311 Achieves Primary Endpoint in Phase III Study for Thyroid Eye Disease

Fineline Cube Feb 20, 2024

Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced that its...

Policy / Regulatory

China’s CDE Issues Guiding Principles for ADC Research and Evaluation

Fineline Cube Feb 20, 2024

China’s Center for Drug Evaluation (CDE) has issued a notification outlining the “Guiding Principles for...

Company Legal / IP Policy / Regulatory

GSK and Peers Respond to FTC Criticism, Withdraw Patent Listings from US Orange Book

Fineline Cube Feb 20, 2024

Three pharmaceutical companies, including the UK’s GSK (NYSE: GSK), have responded to the Federal Trade...

Company Deals

Astellas Pharma Partners with Kelonia Therapeutics to Advance CAR-T Cell Therapies

Fineline Cube Feb 19, 2024

Astellas Pharma Inc. (TYO: 4503) has announced a strategic research collaboration and licensing agreement with...

Company Drug

Denali Therapeutics Faces Setback as ALS Trial Fails to Meet Primary Endpoint

Fineline Cube Feb 19, 2024

Denali Therapeutics (NASDAQ: DNLI) has announced disappointing results from a Phase II trial of its...

Policy / Regulatory

China’s NMPA Releases 77th Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Feb 19, 2024

The National Medical Products Administration (NMPA) has released the 77th batch of reference drugs for...

Policy / Regulatory

GSK’s Avodart Receives NMPA Approval to Resume Sales in China from September

Fineline Cube Feb 19, 2024

The National Medical Products Administration (NMPA) has released a notification announcing that GlaxoSmithKline’s (GSK) Avodart...

Policy / Regulatory

National Health Commission Notification Signals New Poliovirus Containment Measures

Fineline Cube Feb 19, 2024

The National Health Commission (NHC) has issued a notification announcing the establishment of the National...

Policy / Regulatory

China’s NHC Approves 2023 Large Medical Equipment Configuration Licenses, Targets Cancer Treatment

Fineline Cube Feb 19, 2024

The National Health Commission (NHC) has granted approval for the Class A large medical equipment...

Company Drug

Hainan Poly Pharm Wins FDA Nod for Generic Version of UCB’s Vimpat

Fineline Cube Feb 19, 2024

Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...

Company Policy / Regulatory

US Lawmakers Call for Sanctions Against WuXi AppTec and WuXi Biologics Over National Security Concerns

Fineline Cube Feb 19, 2024

US politicians have intensified their opposition to China’s biotech industry, with Congressmen and Senators sending...

Company

Novartis Begins Review of 70% Stake in Indian Unit, Strategic Options Under Consideration

Fineline Cube Feb 18, 2024

Novartis (NYSE: NVS) has initiated a review process concerning its 70.68% stake in Novartis India...

Company Medical Device

Boao Yiling Life Care Center Launches Innovative Dental Technologies Under Pilot Medical Policy

Fineline Cube Feb 18, 2024

Boao Yiling Life Care Center has successfully completed the inaugural use of a dental comprehensive...

Posts pagination

1 … 377 378 379 … 642

Recent updates

  • J&J’s Icotyde Sustains and Improves Complete Skin Clearance in Psoriasis Through 52 Weeks, Outperforming Deucravacitinib on Safety
  • Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Apremilast and Placebo in Phase III Psoriasis Trials with Unprecedented TYK2 Selectivity
  • Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond
  • Sinovac Biotech and Indonesia’s Bio Farma Forge Strategic Alliance to Expand Vaccine Access Across Developing Markets
  • RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai’ai and Disitamab Vedotin
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

J&J’s Icotyde Sustains and Improves Complete Skin Clearance in Psoriasis Through 52 Weeks, Outperforming Deucravacitinib on Safety

Company Drug

Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Apremilast and Placebo in Phase III Psoriasis Trials with Unprecedented TYK2 Selectivity

Company Deals

Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond

Company Deals

Sinovac Biotech and Indonesia’s Bio Farma Forge Strategic Alliance to Expand Vaccine Access Across Developing Markets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.